Transparency notification UCB SA/NV
Brussels (Belgium), 7 April 2021 – 20:00 (CEST) – regulated information
1. Summary of the notification
Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has filed a transparency notification.
The transparency notification dated 7 April 2021 has been submitted in accordance with Article 18 juncto Article 6 of the law of 2 May 2007 on the disclosure of large shareholdings, due to UCB covering its obligations towards employees in the framework of the Long Term Incentive plans of the UCB group. As a result thereof, voting rights relating to voting securities held by UCB SA/NV crossed downwards the 3% threshold on 1 April 2021.
On 1 April 2021, UCB SA/NV owned 5 508 556 UCB shares with voting rights (versus 5 855 888 UCB shares in its previous notification dated 29 March 2021), representing 2.83% of the total number of shares issued by the company (194 505 658) (versus 3.01% in the notification dated 29 March 2020).
2. Content of the notification
- Reason for the notification: Acquisition or disposal of voting securities or voting rights
- Notification by: A person that notifies alone
- Person subject to the notification requirement:
- Date on which the threshold is crossed: 1 April 2021
- Threshold crossed (in %): 3%Denominator: 194 505 658
- Notified details:
- Additional information:
The disclosure obligation arose due to voting rights held by UCB SA crossing downwards the 3% minimum threshold. The variation is due to UCB covering its obligations towards employees in the framework of the Long Term Incentive plans of the UCB group.
3. Further information
This press release and the detailed transparency notification are available on UCB SA/NV’s website via the following link.
An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV’s website via the following link.
Investor Relations, UCB
T +32.2.559.94.14 firstname.lastname@example.orgIsabelle Ghellynck,
Investor Relations, UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 400 people in nearly 40 countries, the company generated revenue of € 5.3 billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
Stay up-to-date on the latest news and information from UCB